Key Insights

Highlights

Treatment Research

1 treatments under study, led by Cytarabinethiotepa Fludarabine Busulfan

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT05598593Phase 2UnknownPrimary

Modified TBF Regimen as Conditioning Regimen Prior to Allo-HSCT for T-ALL/LBL

Showing all 1 trials

Research Network

Common Treatments

  • Cytarabinethiotepa Fludarabine Busulfan1

Active Sponsors

  • First Affiliated Hospital of Zhejiang University1

Top Investigators

  • Yi Luo, M.D.1

    First Affilaated Hospital of Medical School of Zhejiang University

Related Conditions

  • T Cell Acute Lymphoblastic Leukemialymphoblastic Lymphoma1

Activity Timeline